Bharat S Parekh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2916308/publications.pdf

Version: 2024-02-01

71097 98792 5,339 133 41 67 citations h-index g-index papers 134 134 134 3945 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Performance of a novel rapid test for recent HIV infection among newly-diagnosed pregnant adolescent girls and young women in four high-HIV-prevalence districts—Malawi, 2017–2018. PLoS ONE, 2022, 17, e0262071.	2.5	4
2	Geospatial Transmission Hotspots of Recent HIV Infection â€" Malawi, October 2019â€"March 2020. Morbidity and Mortality Weekly Report, 2022, 71, 329-334.	15.1	3
3	Development of a Bead-Based Multiplex Assay for Use in Multianalyte Screening and Surveillance of HIV, Viral Hepatitis, Syphilis, and Herpes. Journal of Clinical Microbiology, 2022, 60, e0234821.	3.9	3
4	Prevalence of and factors associated with late diagnosis of HIV in Malawi, Zambia, and Zimbabwe: Results from population-based nationally representative surveys. PLOS Global Public Health, 2022, 2, e0000080.	1.6	7
5	Performance evaluation of the Asante Rapid Recency Assay for verification of HIV diagnosis and detection of recent HIV-1 infections: Implications for epidemic control. PLOS Global Public Health, 2022, 2, e0000316.	1.6	7
6	Screening for HIV Among Patients at Tuberculosis Clinics â€" Results from Population-Based HIV Impact Assessment Surveys, Malawi, Zambia, and Zimbabwe, 2015â€"2016. Morbidity and Mortality Weekly Report, 2021, 70, 342-345.	15.1	0
7	Recent HIV infection among pregnant women in the 2017 antenatal sentinel cross–sectional survey, South Africa: Assay–based incidence measurement. PLoS ONE, 2021, 16, e0249953.	2.5	24
8	HIV Incidence by Male Circumcision Status From the Population-Based HIV Impact Assessment Surveysâ€"Eight Sub-Saharan African Countries, 2015â€"2017. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, S89-S96.	2.1	5
9	Successful Use of Near Point-of-Care Early Infant Diagnosis in NAMPHIA to Improve Turnaround Times in a National Household Survey. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, S67-S72.	2.1	O
10	Population-Based HIV Impact Assessments Survey Methods, Response, and Quality in Zimbabwe, Malawi, and Zambia. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, S6-S16.	2.1	31
11	A Comprehensive Approach to Assuring Quality of Laboratory Testing in HIV Surveys: Lessons Learned From the Population-Based HIV Impact Assessment Project. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, S17-S27.	2.1	17
12	HIV-1 Recent Infection Testing Algorithm With Antiretroviral Drug Detection to Improve Accuracy of Incidence Estimates. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, S73-S80.	2.1	18
13	HIV incidence, viremia, and the national response in Eswatini: Two sequential population-based surveys. PLoS ONE, 2021, 16, e0260892.	2.5	9
14	Prevalence of nonsuppressed viral load and associated factors among HIVâ€positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from populationâ€based nationally representative surveys. Journal of the International AIDS Society, 2020, 23, e25631.	3.0	29
15	Comparison of HIV Incidence in the Zimbabwe Population-Based HIV Impact Assessment Survey (2015–2016) with Modeled Estimates: Progress Toward Epidemic Control. AIDS Research and Human Retroviruses, 2020, 36, 656-662.	1.1	10
16	High level of HIV false positives using EIA-based algorithm in survey: Importance of confirmatory testing. PLoS ONE, 2020, 15, e0239782.	2.5	5
17	Cost implications of HIV retesting for verification in Africa. PLoS ONE, 2019, 14, e0218936.	2.5	7
18	Field Validation of Limiting-Antigen Avidity Enzyme Immunoassay to Estimate HIV-1 Incidence in Cross-Sectional Survey in Swaziland. AIDS Research and Human Retroviruses, 2019, 35, 896-905.	1.1	22

#	Article	IF	CITATIONS
19	Correlates of HIV infection in adolescent girls and young women in Lesotho: results from a population-based survey. Lancet HIV,the, 2019, 6, e613-e622.	4.7	23
20	An overview of the quality assurance programme for HIV rapid testing in South Africa: Outcome of a 2-year phased implementation of quality assurance program. PLoS ONE, 2019, 14, e0221906.	2.5	5
21	Evaluation of the Performance of Three Biomarker Assays for Recent HIV Infection Using a Well-Characterized HIV-1 Subtype C Incidence Cohort. AIDS Research and Human Retroviruses, 2019, 35, 615-627.	1.1	9
22	Progress toward HIV epidemic control in Lesotho. Aids, 2019, 33, 2393-2401.	2.2	13
23	Tracking with recency assays to control the epidemic. Aids, 2019, 33, 1527-1529.	2.2	35
24	Association between severe drought and HIV prevention and care behaviors in Lesotho: A population-based survey 2016–2017. PLoS Medicine, 2019, 16, e1002727.	8.4	46
25	Proficiency Testing of Viral Marker Screening in African Blood Centers â€" Seven African Countries, 2017. Morbidity and Mortality Weekly Report, 2019, 68, 947-952.	15.1	3
26	Diagnosis of Human Immunodeficiency Virus Infection. Clinical Microbiology Reviews, 2018, 32, .	13.6	51
27	Development of a Multiplex Assay for Concurrent Diagnoses and Detection of HIV-1, HIV-2, and Recent HIV-1 Infection in a Single Test. AIDS Research and Human Retroviruses, 2018, 34, 1017-1027.	1.1	7
28	A Commitment to HIV Diagnostic Accuracy – a comment on "Towards more accurate HIV testing in subâ€Saharan Africa: a multiâ€site evaluation of HIV RDT s and risk factors for false positives―and " HIV misdiagnosis in subâ€Saharan Africa: a performance of diagnostic algorithms at six testing sites― Journal of the International AIDS Society, 2018, 21, e25177.	3.0	11
29	Status of HIV Epidemic Control Among Adolescent Girls and Young Women Aged 15–24 Years — Seven African Countries, 2015–2017. Morbidity and Mortality Weekly Report, 2018, 67, 29-32.	15.1	59
30	Low and Decreasing Prevalence and Rate of False Positive HIV Diagnosis â€" ChókwÃ" District, Mozambique, 2014â€"2017. Morbidity and Mortality Weekly Report, 2018, 67, 1363-1368.	15.1	3
31	Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study. Lancet HIV,the, 2017, 4, e83-e92.	4.7	78
32	Estimating False-Recent Classification for the Limiting-Antigen Avidity EIA and BED-Capture Enzyme Immunoassay in Vietnam: Implications for HIV-1 Incidence Estimates. AIDS Research and Human Retroviruses, 2017, 33, 546-554.	1.1	14
33	Short Communication: Heightened HIV Antibody Responses in Postpartum Women as Exemplified by Recent Infection Assays: Implications for Incidence Estimates. AIDS Research and Human Retroviruses, 2017, 33, 902-904.	1.1	8
34	Returning HIV-1 viral load results to participant-selected health facilities in national Population-based HIV Impact Assessment (PHIA) household surveys in three sub-Saharan African Countries, 2015 to 2016. Journal of the International AIDS Society, 2017, 20, e25004.	3.0	19
35	Mean Recency Period for Estimation of HIV-1 Incidence with the BED-Capture EIA and Bio-Rad Avidity in Persons Diagnosed in the United States with Subtype B. PLoS ONE, 2016, 11, e0152327.	2.5	19
36	Improving the Quality of and Access to HIV Rapid Testing in the Caribbean Region: Program Implementation, Outcomes, and Recommendations. AIDS Research and Human Retroviruses, 2016, 32, 879-884.	1.1	6

#	Article	IF	Citations
37	HIV testing and human rights: the right to the right test. Lancet HIV, the, 2016, 3, e457-e458.	4.7	2
38	Field Evaluation of Four Rapid Tests for Diagnosis of HIV Infection in Panama. Journal of Clinical Microbiology, 2016, 54, 1127-1129.	3.9	5
39	Access and Quality of HIV-Related Point-of-Care Diagnostic Testing in Global Health Programs. Clinical Infectious Diseases, 2016, 62, 369-374.	5.8	25
40	Identifying Risk Factors for Recent HIV Infection in Kenya Using a Recent Infection Testing Algorithm: Results from a Nationally Representative Population-Based Survey. PLoS ONE, 2016, 11, e0155498.	2.5	24
41	Laboratory evaluation of the Chembio Dual Path Platform HIV-Syphilis Assay. African Journal of Laboratory Medicine, 2016, 5, 433.	0.6	7
42	Recalibration of the Limiting Antigen Avidity EIA to Determine Mean Duration of Recent Infection in Divergent HIV-1 Subtypes. PLoS ONE, 2015, 10, e0114947.	2.5	83
43	A Comparison of South African National HIV Incidence Estimates: A Critical Appraisal of Different Methods. PLoS ONE, 2015, 10, e0133255.	2.5	56
44	Evaluation of Performance and Acceptability of Two Rapid Oral Fluid Tests for HIV Detection in Mozambique. Journal of Clinical Microbiology, 2014, 52, 3544-3548.	3.9	22
45	Poor Performance of the Determine HIV-1/2 Ag/Ab Combo Fourth-Generation Rapid Test for Detection of Acute Infections in a National Household Survey in Swaziland. Journal of Clinical Microbiology, 2014, 52, 3743-3748.	3.9	47
46	Development of a Novel Rapid HIV Test for Simultaneous Detection of Recent or Long-Term HIV Type 1 Infection Using a Single Testing Device. AIDS Research and Human Retroviruses, 2013, 29, 61-67.	1.1	25
47	Short Communication: HIV Incidence Among Vulnerable Populations in Honduras: Results from an Integrated Behavioral and Biological Survey Among Female Sex Workers, Men Who Have Sex with Men, and Garifuna in Honduras, 2006. AIDS Research and Human Retroviruses, 2013, 29, 516-519.	1.1	6
48	Strengthening national laboratory health systems in the Caribbean region. Global Public Health, 2012, 7, 648-660.	2.0	13
49	"What Took You So Long?―The Impact of PEPFAR on the Expansion of HIV Testing and Counseling Services in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, S63-S69.	2.1	24
50	Early Diagnosis of HIV Infection in the Breastfed Infant. Advances in Experimental Medicine and Biology, 2012, 743, 51-65.	1.6	3
51	Detection of Recent HIV-1 Infection Using a New Limiting-Antigen Avidity Assay: Potential for HIV-1 Incidence Estimates and Avidity Maturation Studies. PLoS ONE, 2012, 7, e33328.	2.5	180
52	Assessment of BED HIV-1 Incidence Assay in Seroconverter Cohorts: Effect of Individuals with Long-Term Infection and Importance of Stable Incidence. PLoS ONE, 2011, 6, e14748.	2.5	11
53	Determination of Mean Recency Period for Estimation of HIV Type 1 Incidence with the BED-Capture EIA in Persons Infected with Diverse Subtypes. AIDS Research and Human Retroviruses, 2011, 27, 265-273.	1.1	84
54	A Comprehensive Evaluation of the Proficiency Testing Program for the HIV-1 BED Incidence Assay. Journal of Clinical Microbiology, 2011, 49, 3470-3473.	3.9	5

#	Article	IF	Citations
55	HIV testing in developing countries: What is required?. Indian Journal of Medical Research, 2011, 134, 779.	1.0	31
56	Dried tube specimens: A simple and cost-effective method for preparation of HIV proficiency testing panels and quality control materials for use in resource-limited settings. Journal of Virological Methods, 2010, 163, 295-300.	2.1	58
57	Scaling Up HIV Rapid Testing in Developing Countries. American Journal of Clinical Pathology, 2010, 134, 573-584.	0.7	64
58	Evaluating the BED Capture Enzyme Immunoassay to Estimate HIV Incidence Among Adults in Three Countries in Sub-Saharan Africa. AIDS Research and Human Retroviruses, 2010, 26, 1051-1061.	1.1	23
59	Development of Two Avidity-Based Assays to Detect Recent HIV Type 1 Seroconversion Using a Multisubtype gp41 Recombinant Protein. AIDS Research and Human Retroviruses, 2010, 26, 61-71.	1.1	89
60	Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. Journal of Clinical Virology, 2010, 49, 239-244.	3.1	22
61	Current HIVâ€2 diagnostic strategy overestimates HIVâ€2 prevalence in China. Journal of Medical Virology, 2009, 81, 790-797.	5.0	9
62	Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infectious Diseases, The, 2009, 9, 747-759.	9.1	119
63	Alternative Algorithms for Human Immunodeficiency Virus Infection Diagnosis Using Tests That Are Licensed in the United States. Journal of Clinical Microbiology, 2008, 46, 1588-1595.	3.9	150
64	Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. Aids, 2008, 22, 511-518.	2.2	128
65	Mucosal HIVâ€Binding Antibody and Neutralizing Activity in Highâ€Risk HIVâ€Uninfected Female Participants in a Trial of HIVâ€Vaccine Efficacy. Journal of Infectious Diseases, 2007, 196, 1637-1644.	4.0	14
66	Temporal trends in the incidence of HIV infection in antenatal clinic attendees in Addis Ababa, Ethiopia, 1995?2003. Journal of Internal Medicine, 2007, 261, 132-7.	6.0	21
67	Comparison of HIV Type 1 Incidence Observed during Longitudinal Follow-Up with Incidence Estimated by Cross-Sectional Analysis Using the BED Capture Enzyme Immunoassay. AIDS Research and Human Retroviruses, 2006, 22, 945-952.	1.1	129
68	The Epidemiology of Simian Immunodeficiency Virus Infection in a Large Number of Wild- and Captive-Born Chimpanzees: Evidence for a Recent Introduction following Chimpanzee Divergence. AIDS Research and Human Retroviruses, 2005, 21, 335-342.	1.1	36
69	Evaluation of Rapid Prenatal Human Immunodeficiency Virus Testing in Rural Cameroon. Vaccine Journal, 2005, 12, 855-860.	3.1	35
70	Temporal Trends in HIV Type 1 Incidence among Inner-City Childbearing Women in Atlanta: Use of the IgG-Capture BED-Enzyme Immunoassay. AIDS Research and Human Retroviruses, 2005, 21, 537-544.	1.1	27
71	Modification of Rapid Human Immunodeficiency Virus (HIV) Antibody Assay Protocols for Detecting Recent HIV Seroconversion. Vaccine Journal, 2005, 12, 918-921.	3.1	30
72	Surveillance for HIV-1 incidence using tests for recent infection in resource-constrained countries. Aids, 2005, 19, S25-S30.	2.2	65

#	Article	IF	Citations
73	Trends of HIV-1 seroincidence among HIV-1 sentinel surveillance groups in Cambodia, 1999-2002. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 587-92.	2.1	24
74	Application of laboratory methods for estimation of HIV-1 incidence. Indian Journal of Medical Research, 2005, 121, 510-8.	1.0	27
75	Performance Characteristics of the Immunoglobulin G-Capture BED-Enzyme Immunoassay, an Assay To Detect Recent Human Immunodeficiency Virus Type 1 Seroconversion. Journal of Clinical Microbiology, 2004, 42, 2623-2628.	3.9	125
76	Frequent Simian Foamy Virus Infection in Persons Occupationally Exposed to Nonhuman Primates. Journal of Virology, 2004, 78, 2780-2789.	3.4	208
77	Identification in gelada baboons (Theropithecus gelada) of a distinct simian T-cell lymphotropic virus type 3 with a broad range of Western blot reactivity. Journal of General Virology, 2004, 85, 507-519.	2.9	31
78	Multiprotein HIV Type 1 Clade B DNA/MVA Vaccine: Construction, Safety, and Immunogenicity in Macaques. AIDS Research and Human Retroviruses, 2004, 20, 654-665.	1.1	55
79	Characterization of human immunodeficiency virus type-1 from HIV-1 seropositive cases with undetectable viremia. Journal of Clinical Virology, 2004, 30, 224-228.	3.1	4
80	Performance of the OraQuick® and Hema-Strip® rapid HIV antibody detection assays by non-laboratorians. Journal of Clinical Virology, 2004, 30, 229-232.	3.1	46
81	Unsafe injections and transmission of HIV-1 in sub-Saharan Africa. Lancet, The, 2004, 363, 1650.	13.7	6
82	The use of simple, rapid tests to detect antibodies to human immunodeficiency virus types 1 and 2 in pooled serum specimens. Journal of Clinical Virology, 2003, 27, 90-96.	3.1	17
83	HIV Type 1 Incidence Estimates by Detection of Recent Infection from a Cross-Sectional Sampling of Injection Drug Users in Bangkok: Use of the IgG Capture BED Enzyme Immunoassay. AIDS Research and Human Retroviruses, 2003, 19, 727-730.	1.1	54
84	Human Immunodeficiency Virus (HIV) Seropositivity among Uninfected HIV Vaccine Recipients. Journal of Infectious Diseases, 2003, 187, 879-886.	4.0	42
85	Two Percent of HIV-Positive U.S. Blood Donors Are Infected with Non-subtype B Strains. AIDS Research and Human Retroviruses, 2003, 19, 1065-1070.	1.1	27
86	Short Communication: Lack of Evidence for Infection with Simian Immunodeficiency Virus in Bonobos. AIDS Research and Human Retroviruses, 2002, 18, 213-216.	1.1	10
87	Peripheral Blood Cell-Specific Cytokines in Persons with Untreated HIV Infection in Malawi, Africa. AIDS Research and Human Retroviruses, 2002, 18, 1367-1377.	1.1	6
88	Influence of Host Factors on Immunoglobulin G Concentration in Oral Fluid Specimens. Vaccine Journal, 2002, 9, 194-197.	3.1	5
89	HIV Seroincidence Among Patients at Clinics for Sexually Transmitted Diseases in Nine Cities in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 478-483.	2.1	30
90	HIV Seroincidence Among Patients at Clinics for Sexually Transmitted Diseases in Nine Cities in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 478-483.	2.1	37

#	Article	IF	CITATIONS
91	Quantitative Detection of Increasing HIV Type 1 Antibodies after Seroconversion: A Simple Assay for Detecting Recent HIV Infection and Estimating Incidence. AIDS Research and Human Retroviruses, 2002, 18, 295-307.	1.1	322
92	Cytokines and Malaria Parasitemia. Clinical Immunology, 2001, 100, 208-218.	3.2	55
93	HIV-Specific IgG in Cervicovaginal Secretions of Exposed HIV-Uninfected Female Sexual Partners of HIV-Infected Men. AIDS Research and Human Retroviruses, 2001, 17, 1689-1693.	1.1	43
94	Evaluation of a Sensitive/Less-Sensitive Testing Algorithm Using the 3A11-LS Assay for Detecting Recent HIV Seroconversion among Individuals with HIV-1 Subtype B or E Infection in Thailand. AIDS Research and Human Retroviruses, 2001, 17, 453-458.	1.1	57
95	Viral load differences in early infection with two HIV-1 subtypes. Aids, 2001, 15, 683-691.	2.2	97
96	HIV Seroconversion During Pregnancy and Risk for Mother-to-Infant Transmission. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 348-351.	2.1	22
97	Chronic immune stimulation accelerates SIV-induced disease progression. Journal of Medical Primatology, 2001, 30, 254-259.	0.6	25
98	Intracellular cytokines in the acute response to highly active antiretroviral therapy. Aids, 2001, 15, 1665-1670.	2.2	7
99	HIV Seroconversion During Pregnancy and Risk for Mother-to-Infant Transmission. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 348-351.	2.1	16
100	Efficacy of a Less-Sensitive Enzyme Immunoassay (3A11-LS) for Early Diagnosis of Human Immunodeficiency Virus Type 1 Infection in Infants. Vaccine Journal, 2001, 8, 1282-1285.	2.6	0
101	Assessment of Antibody Assays for Identifying and Distinguishing Recent from Long-Term HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2001, 17, 137-146.	1.1	49
102	Induction of Long-Term Protective Effects against Heterologous Challenge in SIVhu-Infected Macaques. Virology, 2000, 278, 194-206.	2.4	14
103	Effect of clinical events on plasma HIV-1 RNA levels in persons with CD4+ T-lymphocyte counts of more than 500 ×106 cells/l. Aids, 2000, 14, 1135-1146.	2.2	2
104	Diagnosis of Human Immunodeficiency Virus Type 1 Infection with Different Subtypes Using Rapid Tests. Vaccine Journal, 2000, 7, 698-699.	2.6	46
105	Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. Aids, 1999, 13, 407-414.	2.2	139
106	Maternal Virus Load and Perinatal Human Immunodeficiency Virus Type 1 Subtype E Transmission, Thailand. Journal of Infectious Diseases, 1999, 179, 590-599.	4.0	132
107	Impact of HIV Type 1 Subtype Variation on Viral RNA Quantitation. AIDS Research and Human Retroviruses, 1999, 15, 133-142.	1.1	127
108	Mucosal disruption due to use of a widely-distributed commercial vaginal product. Aids, 1998, 12, 767-773.	2.2	33

#	Article	IF	CITATIONS
109	Detection of Antibodies to Human Immunodeficiency Virus Type 1 in Oral Fluids: A Large-Scale Evaluation of Immunoassay Performance. Vaccine Journal, 1998, 5, 171-175.	2.6	72
110	Immune stimulation may contribute to enhanced progression of SIV induced disease in rhesus macaques. Journal of Medical Primatology, 1997, 26, 181-189.	0.6	21
111	Presence of HTLV-I and HTLV-II Infection in Honduras. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 308.	0.3	3
112	Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potential. Aids, 1995, 9, 1121-1130.	2.2	6
113	Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 315-319.	7.1	31
114	Infection of a Laboratory Worker with Simian Immunodeficiency Virus. New England Journal of Medicine, 1994, 330, 172-177.	27.0	139
115	Differential replication and pathogenic effects of HIV-1 and HIV-2 in Macaca nemestrina. Aids, 1994, 8, 297-306.	2.2	26
116	Teratogenic Effects of Neonatal Arenavirus Infection on the Developing Rat Cerebellum Are Abrogated by Passive Immunotherapy. Virology, 1993, 197, 669-677.	2.4	29
117	Evaluation of Testing Algorithms Following the Use of Combination HIV-I/HIV-2 EIA for Screening Purposes. AIDS Research and Human Retroviruses, 1993, 9, 147-151.	1.1	15
118	HIV-1 Specific IgG Capture Enzyme Immunoassay to Study the Dynamics of HIV-1 Antibody and to Diagnose HIV-1 Infection in Infants. Annals of the New York Academy of Sciences, 1993, 693, 268-271.	3.8	0
119	Detection of HIV-1 IgA by an IgA Capture Enzyme Immunoassay for Early Diagnosis in Infants. Annals of the New York Academy of Sciences, 1993, 693, 272-274.	3.8	1
120	Dynamics of Maternal IgG Antibody Decay and HIV-Specific Antibody Synthesis in Infants Born to Seropositive Mothers. AIDS Research and Human Retroviruses, 1993, 9, 907-912.	1.1	25
121	Highly specific V3 peptide enzyme immunoassay for seretyping HIV-1 specimens from Thailand. Aids, 1993, 7, 337-340.	2.2	135
122	Human immunodeficiency virus 1-specific IgA capture enzyme immunoassay for early diagnosis of human immunodeficiency virus 1 infection in infants. Pediatric Infectious Disease Journal, 1993, 12, 908-912.	2.0	19
123	Prevalence of HIV-1 and HIV-2 mixed infections in Côte d'Ivoire. Lancet, The, 1992, 340, 337-339.	13.7	77
124	Simian immunodeficiency virus needlestick accident in a laboratory worker. Lancet, The, 1992, 340, 271-273.	13.7	55
125	Factors influencing HIV-1 banding patterns in miniaturized Western blot testing of dried blood spot specimens. Journal of Immunological Methods, 1992, 154, 225-233.	1.4	7
126	Misidentification of HIV-2 proteins by western blots. Lancet, The, 1991, 337, 616-617.	13.7	6

#	Article	IF	CITATIONS
127	Oligomeric nature of transmembrane glycoproteins of HIV-2. Aids, 1991, 5, 1009-1014.	2.2	21
128	Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. Aids, 1991, 5, 1179-1184.	2.2	78
129	Site-specific antibodies define a cleavage site conserved among arenavirus GP-C glycoproteins. Journal of Virology, 1987, 61, 982-985.	3.4	82
130	Molecular and topographic analysis of the glycoproteins of lymphocytic choriomeningitis virus. Medical Microbiology and Immunology, 1986, 175, 71-72.	4.8	3
131	Preparative elution of proteins from nitrocellulose membranes after separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Analytical Biochemistry, 1985, 148, 87-92.	2.4	90
132	Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus. Journal of Virology, 1982, 42, 1029-1038.	3.4	89
133	Equine infectious anemia virus, a putative lentivirus, contains polypeptides analogous to prototype-C oncornaviruses. Virology, 1980, 107, 520-525.	2.4	81